NanoString nCounter: Analytical Validation (MD Anderson)
BRD ID: 3,112
Source: CIMAC-CIDC Network Tier: SOP Number of times downloaded: 10
Description
This assay analytical validation and performance report describes the methods used to validate the nCounter Pan Cancer Panel in conjunction with the Nanostring's nCounter Analysis System using RNA isolated from formalin-fixed, paraffin-embedded (FFPE) tissue specimens. The document also presents data supporting the reported analytical sensitivity using RNA input amounts of 0-625 ng, intra- and inter-assay reproducibility, inter-operator reproducibility, analytical specificity, and differentiation between normal and tumor specimens. It is used by a Cancer Immune Monitoring and Analysis Center (CIMAC) at MD Anderson Cancer Center. It is a product of the CIMAC and Cancer Immunologic Data Center Network (CIMAC-CIDC Network; https://dctd.cancer.gov/ResearchNetworks/cimacs_cidc_network.htm), a Cancer Moonshot Initiative.
Documents for Download
Analytical report_Nanostring_12032018_MDACC_508_Final.pdf [Size: 1939 KB]Biospecimens
- Tissue - Breast
- Tissue - Tonsil
- Tissue - Lung
Diagnoses
- Normal
- Neoplastic - Carcinoma
Topics
- Platform-specific Methodology
Associated SOP Compendiums
- Platform-specific Methodology